Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 86

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Chronic inflammatory demyelinating polyradiculoneuropathy

Not recruiting

Study on the Safety and Effects of NVG-2089 for Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NVG-2089
  • Sponsor:Nuvig Therapeutics Inc.

Primary amyloidosis

Not recruiting

Study of Teclistamab for Patients with Previously Treated AL Amyloidosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Sjogren's syndrome

Not recruiting

Title: Study of Sibeprenlimab Treatment for Adults with Sjögren's Disease Using Subcutaneous Injections

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of Lunsekimig (SAR443765) for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LUNSEKIMIG
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Dermatitis atopic

Not recruiting

Study on the Effectiveness and Safety of RO7790121 for Patients with Moderate to Severe Atopic Dermatitis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ro7790121
  • Sponsor:F. Hoffmann-La Roche AG

Inclusion body myositis

Not recruiting

Title: Long-term safety and effectiveness study of Ulviprubart in patients with inclusion body myositis who completed previous treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:ULVIPRUBART
  • Sponsor:Abcuro Inc.

Conjunctivitis allergic+1

Not recruiting

Study of CLU-RX-BET injection therapy for patients with moderate to severe birch pollen allergies

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:ROXALL Medizin GmbH

Coeliac disease

Not recruiting

Study of TEV-53408 Safety and Effectiveness in Adults with Celiac Disease During Gluten Exposure

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:TEV-53408
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Hereditary angioedema

Not recruiting

Study on the Effect and Safety of BW-20805 for Adults with Hereditary Angioedema

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BW-20805
  • Sponsor:Shanghai Argo Biopharmaceutical Co. Ltd.

VEXAS syndrome

Not recruiting

Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pacritinib
  • Sponsor:Sobi Inc.

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Type 1 diabetes mellitus+1

Not recruiting

Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.